INOUE Hiroaki
Department of Medicine | Assistant Professor A in Medical School |
Last Updated :2024/09/14
■Researcher comments
List of press-related appearances
0
■Researcher basic information
Degree
J-Global ID
Research Keyword
- HIV感染症 悪性リンパ腫
■Career
■Research activity information
Paper
- Takahiro Haeno; Shinya Rai; Yoshiaki Miyake; Maiko Inoue; Ko Fujimoto; Aki Fujii; Yoshio Iwata; Shuji Minamoto; Takahide Taniguchi; Hiroaki Kakutani; Hiroaki Inoue; Takahiro Kumode; Kentaro Serizawa; Yasuhiro Taniguchi; Chikara Hirase; Yasuyoshi Morita; Hirokazu Tanaka; Yoichi Tatsumi; Takashi Ashida; Itaru MatsumuraJournal of clinical and experimental hematopathology : JCEH 63 (2) 99 - 107 2023/06We retrospectively evaluated long-term outcomes of high dose chemotherapy followed by autologous stem cell transplant (HDC/ASCT) in patients with diffuse large B-cell lymphoma (DLBCL). Between 2004 and 2020, 46 DLBCL patients received HDC/ASCT in our institution, including 12 patients (26.1%), who received as an upfront setting (UFS). At a median follow-up time of 69 months (range, 2-169 months), the 5-year progression-free survival (PFS) rates were 82.5% (95%CI, 46.1-95.3%) in the UFS, and 57.8% (95%CI, 38.1-73.2%) in the relapsed or refractory (R/R) patients (n=34), respectively. The 5-year PFS rates were 62.3% (95%CI, 34.0-81.3%) in primary resistant (n=13) or early relapsing (within 1 year from the initial diagnosis) patients (n=4), and 53.3% (95%CI, 25.9-74.6%) in those relapsing >1 year after the initial diagnosis (n=17), with no statistically significant difference (p=0.498). In R/R patients, multivariate analysis showed that the remission status before HDC/ASCT was an independent poor prognostic factor for progression-free survival (hazard ratio [HR], 17.0; 95%CI, 3.35-86.6; p=0.000630) and high-risk category in the international prognostic index for OS (HR, 9.39; 95%CI, 1.71-51.6; p=0.0100). The incidence of non-relapse mortality by 5 years, and 10 years were 12.2%, and 15.2%, respectively. Eleven patients (23.9%) developed second malignancies, which was the most frequent late complication after HDC/ASCT, with 5-year, and 10-year cumulative incidence of 16.9%, 22.5%, respectively. In conclusion, HDC/ASCT is effective for chemo-sensitive R/R DLBCL regardless of the timing and lines of therapy. However, careful observation is required, considering the long-term complications such as secondary malignancies.
- Kentaro Serizawa; Hirokazu Tanaka; Takeshi Ueda; Ayano Fukui; Hiroaki Kakutani; Takahide Taniguchi; Hiroaki Inoue; Takahiro Kumode; Yasuhiro Taniguchi; Shinya Rai; Chikara Hirase; Yasuyoshi Morita; J. Luis Espinoza; Yoichi Tatsumi; Takashi Ashida; Itaru MatsumuraInternational Journal of Hematology Springer Science and Business Media LLC 115 (3) 336 - 349 0925-5710 2022/03
- Shinya Rai; Hiroaki Inoue; Kazuko Sakai; Hitoshi Hanamoto; Mitsuhiro Matsuda; Yasuhiro Maeda; Takahiro Haeno; Yosaku Watatani; Takahiro Kumode; Kentaro Serizawa; Yasuhiro Taniguchi; Chikara Hirase; J Luis Espinoza; Yasuyoshi Morita; Hirokazu Tanaka; Takashi Ashida; Yoichi Tatsumi; Kazuto Nishio; Itaru MatsumuraCancer science 113 (2) 660 - 673 2022/02We previously examined the utility of rituximab-bendamustine (RB) in patients with follicular lymphoma (FL) exhibiting less than optimal responses to 2 cycles of the R-CHOP chemotherapy regimen. The aim of this study was to identify molecular biomarkers that can predict prognosis in RB-treated patients in the context of the prospective cohort. We first analyzed the mutational status of 410 genes in diagnostic tumor specimens by target capture and Sanger sequencing. CREBBP, KMT2D, MEF2B, BCL2, EZH2, and CARD11 were recurrently mutated as reported before, however none was predictive for progression-free survival (PFS) in the RB-treated patients (n = 34). A gene expression analysis by nCounter including 800 genes associated with carcinogenesis and/or the immune response showed that expression levels of CD8+ T-cell markers and half of the genes regulating Th1 and Th2 responses were significantly lower in progression of disease within the 24-mo (POD24) group (n = 8) than in the no POD24 group (n = 31). Collectively, we selected 10 genes (TBX21, CXCR3, CCR4, CD8A, CD8B, GZMM, FLT3LG, CD3E, EOMES, GZMK), and generated an immune infiltration score (IIS) for predicting PFS using principal component analysis, which dichotomized the RB-treated patients into immune IIShigh (n = 19) and IISlow (n = 20) groups. The 3-y PFS rate was significantly lower in the IISlow group than in the IIShigh group (50.0% [95% CI: 27.1-69.2%] vs. 84.2% [95% CI: 58.7-94.6%], P = .0237). Furthermore, the IIS was correlates with absolute lymphocyte counts at diagnosis (r = 0.460, P = .00355). These results suggest that the T-cell-associated immune markers could be useful to predict prognosis in RB-treated FL patients. (UMIN:000 013 795, jRCT:051 180 181).
- Nao Kawano; Hiroaki Inoue; Takahiro ShiratoriThe Journal of dermatology 48 (11) e536-e537 2021/11
- Shinya Rai; Hiroaki Inoue; Hitoshi Hanamoto; Mitsuhiro Matsuda; Yasuhiro Maeda; Yusuke Wada; Takahiro Haeno; Yosaku Watatani; Takahiro Kumode; Chikara Hirase; J Luis Espinoza; Yasuyoshi Morita; Hirokazu Tanaka; Yoichi Tatsumi; Itaru MatsumuraInternational journal of hematology 114 (2) 205 - 216 2021/08The aim of this trial is to evaluate the utility of rituximab-bendamustine (R-B) for untreated advanced follicular lymphoma (FL) showing non-optimal response (nOR) to R-CHOP, and to identify clinical prognostic factors for FL patients receiving R-B. Patients who failed to achieve complete response/complete response unconfirmed (CR/CRu) [nOR-group] after 2 cycles of R-CHOP subsequently received 6 cycles of R-B. The primary endpoint was the 3-year progression-free survival (PFS) rate. Secondary endpoints included determination of prognostic factors. Fifty-six patients initially received R-CHOP, 43/56 patients (76.8%) were judged as nOR, and 33/43 patients (76.7%) completed 6 cycles of R-B. At a median follow-up of 50.6 months in the nOR-group, the 3-year PFS rate was 69.0%, and the 3-year overall survival (OS) rate was 92.7%. The most common toxicities associated with R-B were grade 3-4 lymphopenia (93.0%) and neutropenia (74.4%), both of which were manageable. A multivariate analysis including dose intensity, serum soluble interleukin-2 receptor, and FL international prognostic index-2 revealed low absolute lymphocyte count (< 869/μL) at diagnosis was an independent poor prognostic factor for both PFS and OS in the R-B-treated nOR-group. This result was further confirmed in validation cohorts including R-B-treated de novo (n = 40) and relapsed (n = 49) FL patients.
- Hiroaki Inoue; Shinya Rai; Hirokazu Tanaka; J. Luis Espinoza; Maiko Komori-Inoue; Hiroaki Kakutani; Shuji Minamoto; Takahiro Kumode; Shoko Nakayama; Yasuhiro Taniguchi; Yasuyoshi Morita; Takeshi Okuda; Yoichi Tatsumi; Takashi Ashida; Itaru MatsumuraViruses MDPI AG 12 (4) 416 - 416 2020/04 [Refereed]
Aplastic anemia is a rare blood disease characterized by the destruction of the hematopoietic stem cells (HSC) in the bone marrow that, in the majority of cases, is caused by an autoimmune reaction. Patients with aplastic anemia are treated with immunosuppressive drugs and some of them, especially younger individuals with a donor available, can be successfully treated with hematopoietic stem cell transplantation (HSCT). We report here a rare case of post-transplant lymphoproliferative disorder (PTLD) associated with Epstein–Barr virus (EBV) reactivation in a 30-year-old female patient who underwent allogeneic HSCT for severe aplastic anemia. The PTLD, which was diagnosed 230 days after transplantation, was localized exclusively in the central nervous system (specifically in the choroid plexus) and manifested with obvious signs of intracranial hypertension. After receiving three cycles of high dose methotrexate (HD-MTX) combined with rituximab, the patient achieved a complete clinical recovery with normalization of blood cell counts, no evidence of EBV reactivation, and no associated neurotoxicity. - Hiroaki Inoue; Shinya Rai; Hirokazu Tanaka; J. Luis Espinoza; Yosaku Watatani; Takahiro Kumode; Kentaro Serizawa; Shoko Nakayama; Yasuhiro Taniguchi; Yasuyoshi Morita; Yoichi Tatsumi; Takashi Ashida; Itaru MatsumuraBritish Journal of Haematology 0007-1048 2020 [Refereed]
© 2020 British Society for Haematology and John Wiley & Sons Ltd Despite duodenal-type follicular lymphoma (DTFL) being morphologically, immunophenotypically and genetically indistinguishable from nodal FL (nFL), this entity typically shows a significantly better prognosis. Here, we analysed the tumour immune microenvironments of diagnostic specimens from patients with DTFL (n = 30), limited-stage FL (LSFL; n = 19) and advanced-stage FL (ASFL; n = 31). The mean number of CD8+ tumour-infiltrating lymphocytes (TILs) in the neoplastic follicles was higher in DTFL (1,827/mm2) than in LSFL (1,150/mm2) and ASFL (1,188/mm2) (P = 0·002, P = 0·002, respectively). In addition, CD8+PD1− T cells with non-exhausting phenotype were more abundant in the peripheral blood (PB) of DTFL than in LSFL and ASFL, indicating that DTFL may exhibit a better and longer-lasting T cell-mediated immune response. Moreover, whereas FOXP3+CTLA-4+ effector regulatory T cells (eTregs) were rarely observed in the neoplastic follicles of DTFL (mean: 12/mm2), they were more abundant in LSFL (78/mm2) and ASFL (109/mm2) (P = 2·80 × 10−5, P = 4·74 × 10−8, respectively), and the numbers of eTregs correlated inversely with those of CD8+ TILs (r = −0267; P = 0·018). Furthermore, DTFL showed significantly fewer circulating FOXP3hiCD45RA-CD25hi eTregs (0·146%) than ASFL (0·497%) and healthy controls (0·639%) (P = 0·0003, P = 6·79 × 10−7, respectively). These results suggest that the augmented anti-tumour immune reactions may contribute to a better prognosis on DTFL. - Masashi Kono; Toshiharu Sakurai; Kazuki Okamoto; Tomoyuki Nagai; Yoriaki Komeda; Hiroshi Kashida; Kosuke Minaga; Ken Kamata; Mamoru Takenaka; Satoru Hagiwara; Tomohiro Watanabe; Naoshi Nishida; Eisuke Enoki; Hiroaki Inoue; Itaru Matsumura; Masatoshi KudoInternal medicine (Tokyo, Japan) 58 (14) 2029 - 2033 0918-2918 2019/07 [Refereed]
Autoimmune diseases including inflammatory bowel disease (IBD) occur in association with myelodysplastic syndrome (MDS). MDS-associated IBD frequently demonstrates a complicated course. We herein report the first case with MDS-associated IBD that was successfully treated with ustekinumab (UST), an anti-interleukin (IL) 12/23p40 monoclonal antibody. A 63-year-old man with a 7-year history of MDS was referred for examination of diarrhea, abdominal pain and fever. A blood examination revealed a marked elevation of C-reactive protein. Colonoscopy showed multiple ulcers in the terminal ileum. He was resistant to anti-tumor necrosis factor (TNF)-α antibody and azacitidine. Subsequently, UST treatment reduced colonic IL-17 and IL-6 expression and the patient currently maintains a state of remission. - 岩田吉生; 森田泰慶; 辻潔; 頼晋也; 田崎貴之; 井上宏昭; 谷口康博; 藤本昂; 田中宏和; 芦田隆司; 加藤天美; 松村到PNH Frontier (株)メディカルレビュー社 (6) 46 - 49 2188-4552 2019/07症例は35歳女性で、17歳時に再生不良性貧血-発作性夜間ヘモグロビン尿症(PNH)症候群と診断され、無治療で経過観察されていた。今回、感冒症状が出現し、全身倦怠感・褐色尿などの増悪を認めていた。自室で昏睡状態になっているのを家人が発見し救急要請された。頭部CTでは脳の正中偏移を伴う左前頭葉脳浮腫所見を認め、CT Venographyで上矢状静脈洞の描出欠損を認めた。以上より、上矢状静脈洞血栓症による脳梗塞に起因する意識障害と診断され緊急入院となった。第1病日夜間に意識レベル低下、瞳孔不同の症状が出現し、頭部CTで左前頭葉脳浮腫の増悪を認めたため、緊急開頭減圧術を実施した。さらに、術後侵襲による補体活性化と溶血再燃を抑制する目的で、術後第2病日に髄膜炎菌ワクチンとエクリズマブ投与を開始した。ワルファリンとエクリズマブ投与を継続し、溶血発作の再燃を認めることはなく、第53病日に退院となった。
- Helicobacter pylori eradication in newly diagnosed patients with idiopathic thrombocytopenic purpura井上宏昭; 宮武淳一; 芦田隆司無菌生物 日本無菌生物ノートバイオロジー学会 48 (2) 79 - 81 0910-0903 2018/12
- 宮武淳一; 井上宏昭; 芦田隆司無菌生物 日本無菌生物ノートバイオロジー学会 48 (2) 89 - 90 0910-0903 2018/12
- Shinya Rai; Hirokazu Tanaka; Ko Fujimoto; Takahiro Kumode; Hiroaki Inoue; Yasuhiro Taniguchi; Yasuyoshi Morita; J Luis Espinoza; Yoichi Tatsumi; Takashi Ashida; Ryota Matsuoka; Yukie Yara Kikuti; Naoya Nakamura; Itaru MatsumuraCancers 10 (9) 2018/09 [Refereed]
A 62-year-old male was diagnosed with chronic lymphocytic leukemia (CLL) and treated with a fludarabine-containing regimen which maintained the disease in a partial response. Nine years after diagnosis, a rapidly growing systemic lymphadenopathy was observed, and a biopsy specimen revealed the presence of typical Hodgkin/Reed-Sternberg (HRS) cells, surrounded by T-lymphocytes and CLL cells. Sequencing analysis of the germline complementary determining region 3 (CDR3) region of the immunoglobulin heavy chain (IGH) gene showed that the Hodgkin/Reed-Sternberg cells were clonally unrelated to the preexisting CLL cells and the HRS cells were composed of five different clones, leading to the molecular diagnosis of de novo lymphocyte-rich classic Hodgkin lymphoproliferative diseases (LPDs) with small lymphocytic lymphoma (SLL). As the initial treatment was neither effective for classic Hodgkin LPDs nor for SLL, Bendamustine, Rituximab (BR) was started and complete remission was achieved, which has continued for more than one year so far. BR may be a good therapeutic option for both entities without causing hematological toxicity. - Junichi Miyatake; Hiroaki Inoue; Kentarou Serizawa; Yasuyoshi Morita; J L Espinoza; Hirokazu Tanaka; Takahiro Shimada; Yoichi Tatsumi; Takashi Ashida; Itaru MatsumuraInternal medicine (Tokyo, Japan) 57 (10) 1445 - 1453 0918-2918 2018/05 [Refereed]
Patients with mycosis fungoides (MF), the most common subtype of primary cutaneous T-cell lymphoma, have an increased risk of developing secondary malignancies. We herein report two rare cases of MF concurring with diffuse large B cell lymphoma (B lymphoid lineage) and acute myeloid leukemia (myeloid lineage) in two otherwise healthy elderly patients. Potential etiologic factors, including the impact of the therapy-associated inflammatory response on the development of secondary tumors in patients with MF, are discussed. Further clinical, experimental and genetic studies are needed to elucidate possible physiopathogenic associations among the three concurrent malignancies occurring in the cases presented here. - Masashi Kono; Yoriaki Komeda; Toshiharu Sakurai; Ayana Okamoto; Kosuke Minaga; Ken Kamata; Satoru Hagiwara; Hiroaki Inoue; Eisuke Enoki; Itaru Matsumura; Tomohiro Watanabe; Masatoshi KudoJournal of Crohn's and Colitis Oxford University Press (OUP) 12 (4) 499 - 502 1873-9946 2018/03 [Refereed]
- Hiroaki Inoue; Yasuyoshi Morita; Shinya Rai; Hiroaki Kakutani; Yasuyo Ohyama; Yasuhiro Taniguchi; Hirokazu Tanaka; Takahiro Shimada; Yoichi Tatsumi; Takashi Ashida; Itaru Matsumura[Rinsho ketsueki] The Japanese journal of clinical hematology (一社)日本血液学会-東京事務局 58 (2) 138 - 142 0485-1439 2017/02Immunosuppressive therapy after solid organ transplantation is known to be a risk factor for the development of myelodysplastic syndromes (MDS). Herein, we report 2 patients, both of whom developed low-risk MDS after solid organ transplantation and were successfully treated with azacitidine (AZA). The 1st case was a 74-year-old man who had received liver transplantation. The initial immunosuppressive therapy consisted of cyclosporine and prednisolone. Nine years after transplantation, he was diagnosed as having MDS (RCMD). The 2nd case was a 47-year-old woman who had received cadaveric renal transplantation. The initial immunosuppressive therapy was comprised of cyclosporine, azathioprine, and prednisolone. Twenty-seven years after transplantation, she developed MDS (RA). Both patients received 75 mg/m2 AZA once daily for five consecutive days on a 28-day cycle. After 2 courses of therapy, both patients achieved hematological improvement (IWG 2006 criteria) without severe (grade 3/4) non-hematological adverse events. Moreover, AZA did not affect the status of organ transplantation in terms of engraftment and function of the graft. In conclusion, AZA would be a safe and effective agent for patients with MDS after solid organ transplantation. However, long-term follow-up is needed to confirm the safety and efficacy of AZA for patients undergoing solid organ transplantations.
MISC
- 脳静脈洞血栓症を合併し、開頭減圧術・術後エクリズマブ投与が有効であったPNHの一例(Post-operative treatment with eculizumab for PNH presenting as cerebral venous sinus thrombosis)岩田 吉生; 森田 泰慶; 辻 潔; 頼 晋也; 田崎 貴之; 井上 宏昭; 谷口 康博; 藤本 昂; 田中 宏和; 芦田 隆司; 加藤 天美; 松村 到 臨床血液 59- (9) 1765 -1765 2018/09
- 山田枝里佳; 斉藤花往里; 藤本昂; 角谷宏明; 岩田吉生; 谷口貴英; 源周治; 大山泰世; 口分田貴裕; 井上宏昭; 芹澤憲太郎; 谷口康博; 頼晋也; 平瀬主税; 森田泰慶; 田中宏和; 岡野意浩; 坂田尚己; 芦田隆司; 松村到 日本アフェレシス学会雑誌 37- (Supplement) 2018
- 小森舞子; 井上宏昭; 角谷宏明; 大山泰世; 森田泰慶; 芦田隆司; 松村到 日本造血細胞移植学会総会プログラム・抄録集 39th- 2017
- 芦田隆司; 芦田隆司; 斎藤花往里; 藤本昴; 末田早苗; 角谷宏明; 大山泰世; 井上宏昭; 谷口康博; 頼晋也; 森田泰慶; 岩本ちづる; 中野勝彦; 福島靖幸; 川野亜美; 山田枝里佳; 井手大輔; 前田岳宏; 椿本祐子; 金光靖; 松村到 日本造血細胞移植学会総会プログラム・抄録集 39th- 2017
- 芦田隆司; 芦田隆司; 小森舞子; 波江野高大; 斎藤花往里; 藤本昴; 角谷宏明; 谷口貴英; 佐野圭吾; 大山泰世; 井上宏昭; 口分田貴裕; 森田泰慶; 地守慶亮; 前田朋子; 中野勝彦; 福島靖幸; 川野亜美; 井手大輔; 前田岳宏; 松村到 日本造血細胞移植学会総会プログラム・抄録集 40th- 2017
- 小森舞子; 井上宏昭; 角谷宏明; 大山泰世; 口分田貴裕; 森田泰慶; 田中宏和; 芦田隆司; 田崎貴之; 奥田武司; 松村到 日本造血細胞移植学会総会プログラム・抄録集 40th- 2017
- 小森舞子; 井上宏昭; 角谷宏明; 頼晋也; 森田泰慶; 芦田隆司; 松村到 臨床血液 58- (1) 2017
- 芦田隆司; 芦田隆司; 角谷宏明; 末田早苗; 岩田吉生; 福井彩乃; 大山泰世; 井上宏昭; 頼晋也; 平瀬主税; 森田泰慶; 中野勝彦; 福島靖幸; 川野亜美; 山田枝里佳; 井手大輔; 前田岳宏; 菅野知恵美; 椿本祐子; 金光靖; 松村到; 松村到 日本造血細胞移植学会総会プログラム・抄録集 38th- 2016
- 芹澤憲太郎; 森田泰慶; 江本正克; 大山泰世; 福井彩乃; 井上宏昭; 川内超矢; 金井良高; 平瀬主税; 田中宏和; 嶋田高広; 宮武淳一; 辰巳陽一; 芦田隆司; 松村到 日本造血細胞移植学会総会プログラム・抄録集 36th- 2014
- 芦田隆司; 芦田隆司; 芹澤憲太郎; 川内超矢; 江本正克; 谷口康博; 福井彩乃; 大山泰世; 井上宏昭; 金井良高; 平瀬主税; 森田泰慶; 宮武淳一; 福島靖幸; 川野亜美; 井手大輔; 菅野知恵美; 加藤祐子; 椿本祐子; 伊藤志保; 松村到; 松村到 日本造血細胞移植学会総会プログラム・抄録集 36th- 2014
Lectures, oral presentations, etc.
- COVID-19罹患後に1型糖尿病を発症した2例葉山僚哉; 山下貴史; 村上冴子; 杉本浩嗣; 岩田吉生; 井上宏昭; 花岡郁子日本内分泌学会雑誌 2024
- フォンウィルブランド因子存在下で血腫を来した本態性血小板血症の1例杉本浩嗣; 岩田吉生; 井上宏昭臨床血液 2023
- Outcomes of allo-SCT for patients in non-remission especially with chemoresistance谷口康博; 芦田隆司; 森田泰慶; 平瀬主税; 頼晋也; 中山聖子; 芹澤憲太郎; 口分田貴裕; 井上宏昭; 岩田吉男; 谷口貴英; 源周治; 角谷宏明; 藤本昂; 小森舞子; 波江野高大; 三宅義昭; 辰巳陽一; 田中宏和; 松村到日本造血細胞移植学会総会プログラム・抄録集 2020
- Efficacy of dental extraction in patients with oral diseases prior to allogeneic hematopoietic stem cell transplantation鳥畑さやか; 江原裕基; 助臺美帆; 下出孟史; 金澤仁美; 守屋実央; 安武夏海; 兵頭咲紀; 小森舞子; 源周治; 綿谷陽作; 井上宏昭; 口分田貴裕; 谷口康博; 頼晋也; 森田泰慶; 増田智丈; 榎本明史; 濱田傑; 芦田隆司; 芦田隆司日本造血細胞移植学会総会プログラム・抄録集 2020
- 谷口 貴英; 中山 聖子; 森田 泰慶; 頼 晋也; 平瀬 主税; 谷口 康博; 井上 宏昭; 大山 泰世; 三宅 義昭; Espinoza J Luis; 田中 宏和; 辰巳 陽一; 芦田 隆司; 松村 到日本リンパ網内系学会会誌 2019/05 (一社)日本リンパ網内系学会
- 治療抵抗性TAFRO症候群に合併したAILTの1例 [Not invited]三宅 義昭; 頼 晋也; 井上 宏昭; 口分田 貴裕; 谷口 康博; 中山 聖子; 森田 泰慶; Espinoza J.L.; 田中 宏和; 辰巳 陽一; 芦田 隆司; 松村 到日本リンパ網内系学会会誌 2019/05 (一社)日本リンパ網内系学会
- ヘモグロビン値と血小板数に基づくびまん性大細胞型B細胞リンパ腫、非特異型の新たな予後指標の提唱 [Not invited]中山 聖子; 松田 光弘; 森田 泰慶; 頼 晋也; 谷口 康博; 井上 宏昭; 大山 泰世; 谷口 貴英; 三宅 義昭; 足立 達哉; 末田 早苗; Espinoza J. Luis; 田中 宏和; 辰巳 陽一; 芦田 隆司; 松村 到日本リンパ網内系学会会誌 2019/05 (一社)日本リンパ網内系学会
- 十二指腸原発濾胞性リンパ腫における抗腫瘍免疫の寄与 [Not invited]井上 宏昭; 頼 晋也; 口分田 貴裕; 芹澤 憲太郎; 谷口 康博; 中山 聖子; 森田 泰慶; Luis Espinoza J.; 田中 宏和; 辰巳 陽一; 芦田 隆司; 松村 到日本リンパ網内系学会会誌 2019/05 (一社)日本リンパ網内系学会
- 単一施設における初回同種造血幹細胞移植376例の経年的影響 [Not invited]芦田 隆司; 小森 舞子; 源 周治; 大山 泰世; 井上 宏昭; 口分田 貴裕; 谷口 康博; 頼 晋也; 森田 泰慶; 地守 慶亮; 前田 朋子; 中野 勝彦; 福島 靖幸; 川野 亜美; 井手 大輔; 前田 岳宏; 椿本 祐子; 藤田 往子; 金光 靖; 松村 到日本輸血細胞治療学会誌 2019/04 (一社)日本輸血・細胞治療学会
- 末梢血幹細胞採取前のCD34細胞数測定の有用性 [Not invited]山田 枝里佳; 斉藤 花往里; 藤本 昂; 角谷 宏明; 岩田 吉生; 谷口 貴英; 源 周治; 大山 泰世; 口分田 貴裕; 井上 宏昭; 芹澤 憲太郎; 谷口 康博; 頼 晋也; 平瀬 主税; 森田 泰慶; 田中 宏和; 岡野 意浩; 坂田 尚己; 芦田 隆司; 松村 到日本アフェレシス学会雑誌 2018/10 (一社)日本アフェレシス学会
- 十二指腸型濾胞性リンパ腫は、抗腫瘍免疫により良好な予後を示す(Duodenal-type follicular lymphoma exhibits good prognosis through the increased anti-tumor immunity) [Not invited]井上 宏昭; 頼 晋也; 口分田 貴裕; 芹澤 憲太郎; 谷口 康博; 中山 聖子; 森田 泰慶; ルイス・エスピノザ; 田中 宏和; 辰巳 陽一; 芦田 隆司; 松村 到臨床血液 2018/09 (一社)日本血液学会-東京事務局
- 脳静脈洞血栓症を合併し、開頭減圧術・術後エクリズマブ投与が有効であったPNHの一例(Post-operative treatment with eculizumab for PNH presenting as cerebral venous sinus thrombosis) [Not invited]岩田 吉生; 森田 泰慶; 辻 潔; 頼 晋也; 田崎 貴之; 井上 宏昭; 谷口 康博; 藤本 昂; 田中 宏和; 芦田 隆司; 加藤 天美; 松村 到臨床血液 2018/09 (一社)日本血液学会-東京事務局
- 再生不良性貧血の同種骨髄移植後に中枢神経原発移植後リンパ増殖性疾患を発症した1例 [Not invited]山名 正樹; 寺山 敦之; 森川 みゆき; 寒川 真; 鈴木 秀和; 田崎 貴之; 奥田 武司; 小森 舞子; 井上 宏昭; 楠 進神経免疫学 2017/10 日本神経免疫学会
- FLU+MELは強度減弱移植前処置として適切でない~D‐indexを用いた解析~ [Not invited]芦田隆司; 芦田隆司; 斎藤花往里; 藤本昴; 末田早苗; 角谷宏明; 大山泰世; 井上宏昭; 谷口康博; 頼晋也; 森田泰慶; 岩本ちづる; 中野勝彦; 福島靖幸; 川野亜美; 山田枝里佳; 井手大輔; 前田岳宏; 椿本祐子; 金光靖; 松村到日本造血細胞移植学会総会プログラム・抄録集 2017/02
- 小森舞子; 井上宏昭; 角谷宏明; 大山泰世; 森田泰慶; 芦田隆司; 松村到日本造血細胞移植学会総会プログラム・抄録集 2017/02
- リツキシマブによる間質性肺炎をきたしたDLBCLの1例 [Not invited]小森 舞子; 井上 宏昭; 角谷 宏明; 頼 晋也; 森田 泰慶; 芦田 隆司; 松村 到臨床血液 2017/01
- 膵仮性嚢胞内出血を繰り返す血友病B併存患者に対し、安全に脾合併尾側膵切除と周術期管理を施行し得た1例 [Not invited]村瀬 貴昭; 石川 原; 松本 正孝; 中多 靖幸; 亀井 敬子; 里井 俊平; 松本 逸平; 中居 卓也; 法里 慧; 井上 宏昭; 中尾 慎一; 竹山 宜典日本肝胆膵外科学会・学術集会プログラム・抄録集 2016/06 (一社)日本肝胆膵外科学会
- 膵仮性嚢胞内出血を繰り返す血友病B併存患者に対し,安全に脾合併尾側膵切除と周術期管理を施行し得た1例 [Not invited]村瀬貴昭; 石川原; 松本正孝; 中多靖幸; 亀井敬子; 里井俊平; 松本逸平; 中居卓也; 法里慧; 井上宏昭; 中尾慎一; 竹山宜典日本肝胆膵外科学会学術集会プログラム・抄録集(CD-ROM) 2016/06
- Ph陽性急性リンパ性白血病の同種造血幹細胞移植後の予後はチロシンキナーゼ阻害薬併用寛解導入療法によって改善される [Not invited]芦田隆司; 芦田隆司; 角谷宏明; 末田早苗; 岩田吉生; 福井彩乃; 大山泰世; 井上宏昭; 頼晋也; 平瀬主税; 森田泰慶; 中野勝彦; 福島靖幸; 川野亜美; 山田枝里佳; 井手大輔; 前田岳宏; 菅野知恵美; 椿本祐子; 金光靖; 松村到; 松村到日本造血細胞移植学会総会プログラム・抄録集 2016/02
- 当院における同種造血幹細胞移植時のダプトマイシンの有用性と安全性 [Not invited]芹澤憲太郎; 森田泰慶; 江本正克; 大山泰世; 福井彩乃; 井上宏昭; 川内超矢; 金井良高; 平瀬主税; 田中宏和; 嶋田高広; 宮武淳一; 辰巳陽一; 芦田隆司; 松村到日本造血細胞移植学会総会プログラム・抄録集 2014/02
- 造血幹細胞移植後の真菌感染症に対する低用量アムホテリシンBリポソーム製剤の安全性および有用性に関する検討 [Not invited]芦田隆司; 芹澤憲太郎; 川内超矢; 江本正克; 谷口康博; 福井彩乃; 大山泰世; 井上宏昭; 金井良高; 平瀬主税; 森田泰慶; 宮武淳一; 福島靖幸; 川野亜美; 井手大輔; 菅野知恵美; 加藤祐子; 椿本祐子; 伊藤志保; 松村到日本造血細胞移植学会総会プログラム・抄録集 2014/02
- 真性多血症から移行した急性赤白血病に対して非血縁者間骨髄移植が有効であった1例 [Not invited]芹澤憲太郎; 川西一信; 大山泰世; 尾嶋真由子; 井上宏昭; 口分田貴裕; 江本正克; 谷口康博; 金井良高; 頼晋也; 笹川淳; 平瀬主税; 山口晃史; 森田泰慶; 田中宏和; 嶋田高広; 辰巳陽一; 芦田隆司; 松村到日本造血細胞移植学会総会プログラム・抄録集 2012/02 大阪 第34回日本造血細胞移植学会総会
- 同種造血幹細胞移植前後の血清フェリチン値の移植後の予後に及ぼす影響について [Not invited]芦田隆司; 川野亜美; 山田枝里佳; 井手大輔; 菅野知恵美; 加藤祐子; 椿本祐子; 伊藤志保; 峯佳子; 藤田往子; 井上宏昭; 口分田貴裕; 芹澤憲太郎; 江本正克; 平瀬主税; 山口晃史; 森田泰慶; 川西一信; 辰巳陽一; 松村到日本造血細胞移植学会総会プログラム・抄録集 2012/02
- Analysis of iron overload in patients with transfusion-dependent hematological diseases [Not invited]芦田 隆司; 川野亜美; 山田枝里佳; 井手大輔; 菅野知恵美; 加藤祐子; 椿本祐子; 伊藤志保; 峯 佳子; 藤田往子; 金光 靖; 森嶋祥之; 大山 泰世; 尾嶋 真由子; 井上 宏昭; 口分田 貴裕; 芹澤 憲太郎; 江本 正克; 谷口 康博; 田中 宏和; 金井 良高; 賴 晋也; 笹川 淳; 平瀨 主税; 山口 晃史; 森田 泰慶; 嶋田 高広; 川西 一信; 辰巳 陽一; 松村 到第73回日本血液学会学術集会 2011/10 名古屋 第73回日本血液学会学術集会
- 母児間末梢血幹細胞移植で生着を認めた,維持腹膜透析中の最重症型再生不良性貧血の一例 [Not invited]頼晋也; 松田光弘; 口分田貴裕; 井上宏昭; 川内超矢; 江本正克; 芹澤憲太郎; 金井良高; 山口晃史; 森田泰慶; 嶋田高広; 宮武淳一; 辰巳陽一; 芦田隆司; 前田裕弘; 松村到日本造血細胞移植学会総会プログラム・抄録集 2011
- A young case diagnosed concomitantly as B-CLL and B-cell lymphoma [Not invited]賴 晋也; 辰巳 陽一; 口分田 貴裕; 井上 宏昭; 川内 超矢; 江口 剛; 大山 雄一; 山口 晃史; 森田 泰慶; 嶋田 高広; 宮武 淳一; 芦田 隆司; 前田 裕弘; 松村 到; 松田 光弘第72回 日本血液学会学術集会 2010/09 横浜 第72回 日本血液学会学術集会
- 急性混合性白血病を発症し、同種骨髄移植にて寛解維持するも一年後骨腫瘤病変にて再発し再移植した症例 [Not invited]江口 剛; 山口 晃史; 口分田 貴裕; 井上 宏昭; 川内 超矢; 大山 雄一; 賴 晋也; 森田 泰慶; 嶋田 高広; 川西 一信; 宮武 淳一; 辰巳 陽一; 芦田 隆司; 前田 裕弘; 松村 到; 金丸 昭久; 佐野 徹明第20回 南近畿血液病フォーラム 2010/07 大阪 第20回 南近畿血液病フォーラム
- 付加的染色体転?(7;17)を伴った慢性骨髄性白血病(CML)の巨核芽球性急性転化症例 [Not invited]井上 宏昭; 嶋田 高広; 山口 晃史; 森田 泰慶; 川西 一信; 宮武 淳一; 芦田 隆司; 前田 裕弘; 松村 到; 辰巳 陽一第93回 近畿血液学地方会 2010/06 大阪 第93回 近畿血液学地方会